Overview
Lobbying Costs
250,000€
Financial year: Jan 2018 - Dec 2018
Lobbyists (Full time equivalent)
0.75 Fte (3)
Lobbyists with EP accreditation
0
High-level Commission meetings
6
Lobbying Costs over the years
-
Info
AbbVie (ABBV)
EU Transparency Register
934069612666-51 First registered on 20 Jan 2014
Goals / Remit
AbbVie is a Specialty-focused, research-based biopharmaceutical company.
We are approximately 30,000 people focused on developing new products and new ways to help people manage some of the most serious health conditions. We are scientists, researchers, communicators, manufacturing specialists, and regulatory experts.
AbbVie began as the pharmaceutical leader, Abbott, which was founded in 1888 by Chicago physician, Dr. Wallace Abbott. Since then, Abbott has evolved to become a global healthcare leader, delivering innovative pharmaceutical, nutritional, diagnostic, and medical products to people in more than 150 countries.
On January 1, 2013, AbbVie was founded, a global biopharmaceutical company with the focus and capabilities to address some of the world's greatest health challenges. AbbVie has the stability, resources, expertise, and passion to discover, develop, and bring to market groundbreaking science to solve the biggest health problems that face the world today and tomorrow.Main EU files targeted
- Implementation of the regulation on Clinical Trials
- Implementation of the legislation on Falsified Medicines
- Joint Procurement for medical countermeasures
- Commission expert group on safe and timely access for patients
- Prevention and Early Intervention in Chronic Diseases
- Demographic change and healthy ageing
- Competition in the pharmaceutical sector
- Pharmaceutical industrial policy including intellectual property policies
- Revision of Medical Device and IVD Regulation
- European Commission activities around ensuring effective, resilient and sustainable healthcare systems
- Access to MedicinesAddress
Head Office
North Waukegan Road, 1
North Chicago IL 60064
UNITED STATESEU Office
Regus Offices - offices 507-508
Square de Meeus 37
Brussels 1000
BELGIUM -
People
Total lobbyists declared
3
Employment time Lobbyists 25% 3 Lobbyists (Full time equivalent)
0.75
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 01 Oct 2019
Name Start date End Date Philip SCHWAB 07 Jun 2023 06 Jun 2024 Christian BARACAT 22 Sep 2023 20 Sep 2024 Janusz LINKOWSKI 20 Mar 2024 02 Oct 2024 Felix KUBITSCHEK 22 Sep 2023 01 Feb 2024 Felix KUBITSCHEK 12 Jul 2022 12 Jul 2023 Christian BARACAT 25 Jun 2022 24 Jun 2023 Ms Jennifer SHUM 05 Feb 2016 02 Feb 2017 Complementary Information
While 3 persons are engaged in activities falling under the scope of the Transparency Register, each person's dedicated working time towards specific activities covered by the register does not account for 25% of their respective working time.
Person in charge of EU relations
Mr Ludovic Lacaine (Government Affairs Director, Brussels/EU)
Person with legal responsibility
Mr Richard A. Gonzalez (Chairman of the Board and Chief Executive Officer)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
- American Chamber of Commerce to the EU
- European Federation of Pharmaceutical Industries and Association (EFPIA)
- European Biopharmaceutical Enterprises (EBE)
- EuropaBio – the European Association of Bio-IndustriesMember organisations
None declared
-
Financial Data
Closed financial year
Jan 2018 - Dec 2018
Lobbying costs for closed financial year
250,000€
Other financial info
In order to avoid double reporting on the Register, this figure excludes trade association membership fees.
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
None
Other activities
- Raise awareness about healthy ageing and healthcare sustainability
- Increase Europe’s competitiveness as a hub for R&D investments
- Work towards a regulatory and Intellectual property framework that fosters innovation and improves access to patients- Meetings
Meetings
6 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 21 Sep 2023 Location Ireland Subject Discussions covered AbbVie’s presence in Europe including 5 major sites in Ireland; the sector’s demand for skills and training; the pharmaceutical strategy for Europe and access to medicine in Ireland. Cabinet Cabinet of Commissioner Mairead Mcguinness Portfolio Financial services, financial stability and Capital Markets Union Attending - Mairead McGuinness (Commissioner)
- Patricia Reilly (Cabinet member)
-
Date 05 Jun 2023 Location Brussels Subject Trade & Technology Council, Global Steel and Aluminum Arrangement, Critical Minerals Agreement Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis Portfolio An Economy that Works for People Attending - Zaneta Vegnere (Cabinet member)
- Elina Melngaile (Cabinet member)
Other Lobbyists - Intel Corporation
- John Deere GmbH&Co.Kg
- Pharmaceutical Research and Manufacturers of America
- Boeing International Corporation - Belgium Branch Office
- Abbott
- Merck
- American Chamber of Commerce to the European Union
- Chamber of Commerce of the United States of America
- IBM Corporation
- BGP Products Operations GmbH – a Viatris Company
- Shopify Inc.
- Dow Europe GmbH
- ConocoPhillips
- AIG Europe S.A.
- Micron Technology Inc.
-
Date 24 Nov 2020 Location Brussels (online) Subject Pharmaceutical innovation and research in Europe Cabinet Cabinet of Executive Vice-President Margrethe Vestager Portfolio Europe Fit for Digital Age Attending - Alina-Stefania Ujupan (Cabinet member)
-
Date 24 May 2018 Location Brussels Subject Business discussion Cabinet Cabinet of Commissioner Phil Hogan Portfolio Agriculture & Rural Development Attending - Tom Tynan (Cabinet member)
-
Date 27 Mar 2018 Location Brussels Subject IP regime generic manufacturers in the pharmaceutical industry Cabinet Cabinet of Commissioner Pierre Moscovici Portfolio Economic and Financial Affairs, Taxation and Customs Attending - Leila Fernandez-Stembridge (Cabinet member)
-
Date 26 Mar 2018 Location Brussels Subject SPC waiver Cabinet Cabinet of Vice-President Cecilia Malmström Portfolio Trade Attending - Nele Eichhorn (Cabinet member)
Other Lobbyists
- Meetings